Jefferies Group Reiterates “Buy” Rating for Axovant Sciences Ltd. (AXON)
Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group in a report issued on Monday. They currently have a $31.00 price target on the stock. Jefferies Group’s price objective suggests a potential upside of 112.47% from the company’s previous close.
AXON has been the subject of a number of other research reports. Piper Jaffray Cos. set a $32.00 target price on Axovant Sciences and gave the company a “buy” rating in a report on Friday, September 23rd. JMP Securities reissued an “outperform” rating and issued a $36.00 target price on shares of Axovant Sciences in a report on Tuesday, August 16th. Robert W. Baird reissued an “outperform” rating and issued a $29.00 target price on shares of Axovant Sciences in a report on Friday, September 23rd. Leerink Swann started coverage on Axovant Sciences in a report on Tuesday, June 7th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a report on Tuesday, June 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.21.
Shares of Axovant Sciences (NYSE:AXON) opened at 14.59 on Monday. Axovant Sciences has a one year low of $8.86 and a one year high of $21.30. The stock’s market cap is $1.45 billion. The company has a 50 day moving average of $15.95 and a 200-day moving average of $13.51.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings results on Monday, August 15th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. On average, analysts anticipate that Axovant Sciences will post ($1.69) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of AXON. Ghost Tree Capital LLC bought a new stake in Axovant Sciences during the second quarter worth approximately $7,383,000. Citadel Advisors LLC boosted its stake in Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock worth $7,353,000 after buying an additional 512,413 shares in the last quarter. VHCP Management II LLC bought a new stake in Axovant Sciences during the first quarter worth approximately $4,932,000. BlackRock Fund Advisors boosted its stake in Axovant Sciences by 69.2% in the second quarter. BlackRock Fund Advisors now owns 574,250 shares of the company’s stock worth $7,373,000 after buying an additional 234,904 shares in the last quarter. Finally, Sabby Management LLC boosted its stake in Axovant Sciences by 458.2% in the second quarter. Sabby Management LLC now owns 190,000 shares of the company’s stock worth $2,440,000 after buying an additional 155,960 shares in the last quarter. Hedge funds and other institutional investors own 29.45% of the company’s stock.
About Axovant Sciences
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.